BUSINESS

Teva Takeda JVs Curb Shipments of 8 Products in Quake Fallout

January 31, 2024

Teva Takeda Pharma and Teva Takeda Yakuhin said on January 30 that they are restricting their shipments of eight products as the New Year’s earthquake caused delays in the deliveries of some products from a contract manufacturer.

The companies decided on the move to ensure stable drug supplies amid the delivery delay from Kokando. Subject to the restrictions are one product owned by Teva Takeda Pharma as the marketing authorization holder, Candesartan Tablets 8 mg “Takeda Teva”, as well as seven products held by Teva Takeda Yakuhin - Cercine Tablets 2 mg (diazepam), Takelda Combination Tablets (lansoprazole + aspirin), Ecard Combination Tablets LD/HD (candesartan + hydrochlorothiazide), Takepron OD Tablets 15/30 (lansoprazole), and Blopress Tablets 2 (candesartan).

BUSINESS

Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…

By Tatsuya Otsuka

Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…

By Philip Carrigan

We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…

Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…

By Ken Yoshino

The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…

The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…

Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…